Aperture Bio Ready to Introduce its Diagnostic Platform to Combat Antibiotic Resistance Through Rapid Detection of Bacterial Infections & Antibiotic Profiling within Hours
Utilizing highly customized and fully robotic next-gen flow cytometric technology (nFC), coupled with proprietary chemistry and customized platting, the RAPID-BTM platform can discriminate live uropathogen bacteria from those that are dead/damaged, as well as, normal urogenital contaminants, which could result in false positives and lead to unnecessary treatment.
Centered around a sensitive array of lasers, the system enumerates only viable bacteria and white blood cells within minutes and provides Antibiotic Predictive Profiling (APP) within hours. Specifically knowing which patients to treat and providing a rapid, categorical assessment of treatment options could both greatly reduce the risks for millions of patients being unnecessarily overexposed to antibiotics and save millions in healthcare costs.
Achieving 98% sensitivity and 88% specificity, the empiriSTAT-UTI is the first in a series of in vitro tests developed to increase the speed and accuracy of identifying bacterial infections from both urine and blood. The speed and accuracy of the test will reduce turn-around-times with actionable results from days to hours when compared to current screen, culture and reflexed Antibiotic Susceptibility Testing (AST.) By rapidly isolating those patients that are negative vs. positive aids healthcare professionals to quickly and accurately identify not only those patients that may require further treatment, but equally as important, those that do not require antibiotic treatments.
The urgent need to reduce the overuse and misuse of antibiotics through empirical prescribing is at the forefront of the world's public health agencies;
The United Nations (U.N.'s) Interagency Coordination Group on Antimicrobial Resistance released a report in 2019 stating that "drug-resistant infections will kill 10 million people annually by 2050? and specifically calls for "more initiatives aimed at limiting unnecessary antibiotic use."
The World Health Organization (WHO) states, "Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally. Without urgent action, we are heading for a post- antibiotic era in which common infections and minor injuries can once again kill."
The Commissioner of the Food & Drug Administration (FDA) stated that "Antimicrobial resistance is a global public health challenge. Combating antimicrobial resistance continues to be a top priority. Our aim is to reduce overuse of antimicrobial drugs and combat the rising threat of resistance."
The Infectious Disease Society of American (IDSA) stated "Because treatment of acute uncomplicated cystitis is usually empirical, it is likely that some women will be treated with a drug that does not have in vitro activity against the uropathogen. As the population resistance prevalence of a specific agent increases, the likelihood of failure outweighs the benefits of using the drug empirically."
The unintentional overuse and misuse of antibiotics is, in great part, due to the empirical over-prescribing in a partially 'blind,? defensive response by caregivers as they await lab results. With reports suggesting that +/-90% of blood and +/-60% of urine cultures come back negative, the ability to accurately and rapid discriminate positive vs. negative patients within minutes for urine, and a few hours in blood, could significantly reduce this overuse and misuse, which is at the foundation of the antibiotic resistance pandemic.
The speed and accuracy of the empiriSTAT test has demonstrated to out-perform other screening methods including chemical strips, microscopy and PCR. Even standard urinalysis screening, which is semiquantitative and lacks precision and standardization, results in a high rate of misinterpretation, which can lead to under-treatment, or more often, over-treatment with empirical antibiotics. When compared to current screening and culture methodology accompanied with follow through AST testing, which all can take days, the RAPID-BTM could change how bacterial infections are detected and treated, disrupting the multi-billion-dollar laboratory testing industry.
In a statement from Matthew Gombrich, MD, M.S, Chief Medical Officer at Aperture Bio, 'in an era of alarming rates of antibiotic resistance, the negative predictive value of what we have achieved cannot be overstated. Reducing the overuse and misuse of antibiotics through new technology like the RAPID-B could help save millions of lives and billions of dollars ...and should be in the hands of healthcare providers today."
Aperture Bio is a privately held laboratory diagnostic company whose focus is to bring emerging technologies to market aimed at addressing antibiotic resistance and other world health issues. The company is currently seeking B Series investors to further expand its product offering and the commercialization of its proprietary RAPID-BTM platform. For investment opportunities, please contact Mr. David Potenza email@example.com
Aperture Bio, LLC
20 Winter Sport Ln
Williston, VT 05495
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aperture Bio Ready to Introduce its Diagnostic Platform to Combat Antibiotic Resistance Through Rapid Detection of Bacterial Infections & Antibiotic Profiling within Hours here
News-ID: 1730349 • Views: 1217
More Releases from Aperture Bio
Aperture Bio to Begin Accepting Pre-orders for its RAPIB-B(TM) Quantitative Micr …
(Dallas, TX – 6/24/19) - www.Aperturebio.com. In response to the growing demand for advanced diagnostic tools to aid in the fight of overused and misused antibiotics, Aperture Bio has begun accepting pre-orders of its RAPID-B(TM) and its empiriSTAT menu of diagnostic tests. In a statement from Aperture Bio’s president, David Potenza, “With world health agencies calling for increased action to combat resistance, and no new antibiotics on the horizon, healthcare
Aperture Bio seeks B Series Funding as it Completes Final FDA Submission and Pre …
Responding to increased demand for its proprietary RAPID-B(TM) diagnostic platform and empiriSTAT test menu, Aperture Bio has announced its intention to seek B Series investors as it heads to full commercialization. The company is looking to enter the clinical diagnostics market, which is valued at US$168 billion and growing at a 7.3% CAGR, according to data released by Coherent Market Insights in 2015. In a statement from Aperture’s president, David Potenza,
Aperture Bio & NuView Life Sciences Sign Definitive Agreement to Investigate Exp …
(Dallas, TX/Salt Lake City, UT) – In a joint press release, Aperture Bio and NuView Life Sciences have entered into an agreement to begin collaborative investigational studies to assess NuView’s proprietary NV-VPAC1(TM) urogenital cancer test utilizing Aperture Bio’s RAPID-B(TM) proprietary screening platform. Aperture Bio has developed a proprietary diagnostic platform, the RAPID-BTM, designed for rapid and accurate detection of bacterial infections found in both urine and blood specimens. The
Aperture Bio Invited to Present at Antimicrobial Resistance World Congress
(Dallas, TX – 5/13/19) - www.Aperturebio.com – Aperture Bio announces it has been invited to present at the WORLD ANTIMICROBIAL RESISTENCE CONGRESS on November 7-8 in Washington, D.C. Aperture will present its RAPID-BTM in vitro diagnostic platform for the rapid detection of bacterial infections and antibiotic profiling, which could assist caregivers reduce the need for empirical overprescribing of antibiotics. The event will host some +600 attendees from over
More Releases for Antibiotic
Topical Antibiotic Pharmaceuticals Market Investment Research Report 2016 - 2022
Topical antibiotics pharmaceuticals are used to treat infections of the skin and are commonly applied as creams and ointments. Antibiotics are agents that destroy or inhibit the growth of microorganisms, which are sensitive to them. Few topical antibiotics are sold without prescription from physicians and are available in several forms such as ointments, creams, sprays and powders. Topical antibiotics prevents infection caused by bacteria which get into minor scrapes, burns,
Antibiotic Market Estimated to Flourish by 2016 - 2024
Global Antibiotic Market: Overview Antibiotics, also called antibacterials or antimicrobials, is a group of medicines used in the treatment of infections caused by germs—bacteria and certain parasites—by inhibiting the growth of microorganisms or killing them. Since the discovery of the antibiotic penicillin in 1920, various antibiotic compounds have been widely used to treat several bacterial infections. Increasing incidence of chronic and infectious diseases across the globe and efficacy of antibiotics to
Latest developments and breakthroughs in antibiotic resistance
The growing global threat of antimicrobial resistance, research strategies aiming to eliminate resistance, latest scientific advancements for tackling resistance, as well as potential novel candidates and antimicrobial alternatives is the focus for SMi’s 20th annual Superbugs and Superdrugs conference. It will take place in Copthorne Tara Hotel, Kensington, London on the 19th and 20th March. The topic of Superbugs & Superdrugs has continuously evolved and developed in the two decades the
Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals Market Highlighted k …
Sulfonamides are a group of drugs that are derived from sulfanilamide, a sulfur containing compound. Sulfonamides are the most commonly used antibiotics around the world and have been in clinical use since 1968. Sulfonamides, also known as anti-metabolites and sulfa drugs act by inhibiting the folic acid synthesis pathway in a bacterial cell. These antibiotics are considered as selective targeted option since human do not synthesize folic acid, but a
“SPARKing" New Antibiotic Drug Discovery
Kathy Talkington, Project Director from Pew Charitable Trusts, will discuss the "Shared Platform for Antibiotic Research and Knowledge" when she presents a keynote on "SPARKing" new antibiotic drug discovery at SMi’s 20th annual conference on Superbugs and Superdrugs next March in Central London. With a background in managing and developing immunization and infectious disease programs and policies, Kathy Talkington is currently responsible for Pew’s work on antibiotics. Pew seeks to address
Research Offers 10-Year Forecast on Topical Antibiotic Pharmaceuticals Market
Topical antibiotics are applied to a certain area of the skin to kill infections. Application of topical antibiotics has a number of advantages upon comparison of systemic delivery in the treatment of skin infections. Skin and soft tissue infections (SSTIs) involve microbial invasion of the skin and underlying soft tissues infections are one of the most commonly occurring conditions amongst people. Most of these infections are minor and chronic in